Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
110.56 x 1 111.50 x 11
Post-market by (Cboe BZX)
111.16 +1.89 (+1.73%) 03/27/25 [NASDAQ]
110.56 x 1 111.50 x 11
Post-market 111.50 +0.34 (+0.31%) 19:56 ET
Profile for Thu, Mar 27th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.

Company Info

Gilead Sciences Inc 333 LAKESIDE DRIVE FOSTER CITY CA 94404 USA

www.gilead.com Employees: 17,600 P: 650-574-3000 F: 650-522-5853

Sector:

Medical

Description:

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

Key Statistics

Overview:

Market Capitalization, $K 136,078,944
Enterprise Value, $K 154,093,952
Shares Outstanding, K 1,245,346
Annual Sales, $ 28,754 M
Annual Net Income, $ 480,000 K
Last Quarter Sales, $ 7,569 M
Last Quarter Net Income, $ 1,783 M
EBIT, $ 1,662 M
EBITDA, $ 4,429 M
60-Month Beta 0.21
% of Insider Shareholders 0.16%
% of Institutional Shareholders 83.67%
Float, K 1,243,353
% Float 99.84%
Short Volume Ratio 0.30

Growth:

1-Year Return 52.25%
3-Year Return 86.29%
5-Year Return 42.13%
5-Year Revenue Growth 28.09%
5-Year Earnings Growth -24.76%
5-Year Dividend Growth 22.22%

Per-Share Information:

Most Recent Earnings 1.90 on 02/11/25
Next Earnings Date 04/24/25
Earnings Per Share ttm 4.61
EPS Growth vs. Prev Qtr -5.94%
EPS Growth vs. Prev Year 10.47%
Annual Dividend Rate, $ 3.10
Annual Dividend Yield 2.84%
Most Recent Dividend 0.790 on 03/14/25
Next Ex-Dividends Date 03/14/25
Dividend Payable Date 03/28/25
Dividend Payout Ratio 66.19%
Most Recent Split 2-1 on 01/28/13

GILD Ratios

Ratio
Price/Earnings ttm 23.40
Price/Earnings forward 13.71
Price/Earnings to Growth 0.70
Return-on-Equity % 31.63%
Return-on-Assets % 10.38%
Profit Margin % 1.67%
Debt/Equity 1.46
Price/Sales 4.67
Price/Cash Flow 15.70
Price/Book 6.99
Book Value/Share 15.44
Interest Coverage -1.71

GILD Dividends

Date Value
03/14/25 $0.7900
12/13/24 $0.7700
09/13/24 $0.7700
06/14/24 $0.7700
03/14/24 $0.7700
12/14/23 $0.7500
09/14/23 $0.7500
06/14/23 $0.7500
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies